By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Medical Answers > How long does it take Vyepti to work?

How long does it take Vyepti to work?

Answers by TheMediTary.Com - Last updated: 13-Jul-2023

Vyepti can work as quickly as the first day or week after your first intravenous (IV) infusion to help prevent your migraine headache pain.

Vyepti (eptinezumab) is given as a 30 minute intravenous (IV) infusion at a clinic every 3 months (4 times per year). It is not used to treat migraine headaches that have already started. Once the infusion is done, most people can go back to their normal daily activities.

The recommended dose is 100 mg IV given every 3 months; some patients may benefit from a dose of 300 mg.

Related: Treatment and Prevention Tips for Living with Migraine Headaches

PROMISE-1 and PROMISE-2 were two Vyepti Phase 3 clinical studies where researchers looked at how well Vyepti worked and at its safety.

  • PROMISE-1 was done in patients with episodic migraine and PROMISE-2 was done in chronic migraine.
  • Vyepti had a treatment benefit over placebo (an inactive medicine) for both the 100 mg and 300 mg doses of Vyepti as early as the first day after the initial infusion.
  • The percentage of patients experiencing a migraine was lower for Vyepti than with placebo for most of the first 7 days.

The most common side effects (≥2%) were nasopharyngitis (common cold, stuffy nose and scratchy throat) and hypersensitivity (allergic reactions). In studies, 1% to 2% of patients experienced an allergic reaction, compared to 0% in the placebo group. Some allergic reactions may be severe (for example: anaphylaxis, angioedema) and require treatment or discontinuation of treatment.

Is Vyepti a CGRP antagonist?

Yes, Vyepti is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

  • CGRP is a protein found in the sensory nerves of the head and neck area. CGRP can lead to inflammation and migraine headache pain by causing the blood vessels to dilate.
  • Studies have suggested there may be a connection between CGRP, CGRP receptors, and migraine.

Vyepti was approved by the FDA in February 2020 and is manufactured by Lundbeck Inc.

Learn more: New Drugs for the Treatment of Migraine Headache

This is not all the information you need to know about Vyepti (eptinezumab) for safe and effective use and does not take the place of your doctor’s directions. Review the full Vyepti information and discuss this information and any questions you have with your doctor or other health care provider.

Share this Article

Featured questions

  • How is Vyepti different from Aimovig?
  • Does Vyepti cause weight gain?
  • Can Vyepti cause fatigue?
  • How long do Vyepti infusions take?
  • Can these drugs be used in Thalassemia patients?
  • How does Lupron (leuprolide) work for prostate cancer?
  • What is the consideration to use nifidepine over amlodipine?
  • Hypertrophic cardiomyopathy/mechanical heart valve?
  • I have been on 400mg of tramadol a day for 20 years, decided its time to come off them
  • Cetirizine - can cetirizine be taken for long periods of time?
  • In the 1960 and 1970 what was used to treat server asthma?
  • High dosage of escitalopram?
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch (Hydrocortisone topical)
Centrum Adult (Multivitamins and minerals)
Crovalimab
Cyltezo Prefilled Syringe (Adalimumab)
Zepbound Pen (Tirzepatide)
Mylanta One (Calcium carbonate, magnesium hydroxide, and simethicone)
Uretron Ds (Hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate)
Medihoney Wound And Burn Dressing (Topical emollients)
Lidotrode
Libervant (Diazepam (buccal))
Moderna Covid-19 (Covid-19 (6m-11y) vaccine, moderna (2024-2025))
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by